期刊
VIRUS RESEARCH
卷 239, 期 -, 页码 69-81出版社
ELSEVIER
DOI: 10.1016/j.virusres.2016.10.019
关键词
HIV-1; HIV resistance; Next-generation sequencing; Antiretroviral therapy; Low-frequency variants; Tropism
类别
资金
- Red de Investigacion en SIDA (RIS) as part of Spanish Plan Nacional R+D+I [RD12/0017/0006]
- ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER)
- Gala contra la Sida - Barcelona
The emerging HIV-1 resistance epidemic is threatening the impressive global advances in HIV-1 infection treatment and prevention achieved in the last decade. Next-generation sequencing is improving our ability to understand, diagnose and prevent HIV-1 resistance, being increasingly cost-effective and more accessible. However, NGS still faces a number of limitations that need to be addressed to enable its widespread use. Here, we will review the main NGS platforms available for HIV-1 diagnosis, the factors affecting the clinical utility of NGS testing and the evidence supporting-or not- ultrasensitive geno-typing over Sanger sequencing for routine HIV-1 diagnosis. Now that global HIV-1 eradication might be within our reach, making NGS accessible also to LMICs has become a priority. Reductions in sequencing costs, particularly in library preparation, and accessibility to low-cost, robust but simplified automated bioinformatic analyses of NGS data will remain essential to end the HIV-1 pandemic. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据